ATCC 100 Years Logo Anniversary ATCC 100 Years Logo Anniversary Cart 0
  • Quick Order
  • Careers
  • Support

Episode 35: The Brains Behind the Barriers

Featuring Drs. Susan Roelofs and Elena Geervliet

Listen on Apple Podcasts button Listen on YoutUbe Music button Listen on Spotify button Listen on Pandora button

Show Notes:

In the second episode of our series featuring Drs. Susan Roelofs and Elina Geervliet, the discussion revolves around the development of Locsense and the Artemis instrument. Dr. Geervliet shares her journey into biomedical engineering, emphasizing the importance of education for understanding R&D needs. Dr. Roelofs, who has always aimed for entrepreneurship, highlights how her diverse experiences shaped her path. The conversation also touches on the challenges Locsense faced in transitioning from research to market and the significance of collaboration in product development. Ultimately, the discussion reveals the importance of seizing timely opportunities in the field.

Guests:

Susan Roelofs.jpeg

Susan Roelofs, PhD

CEO and Founder, Locsense

Dr. Susan Roelofs is the CEO and founder of Locsense B.V., a pioneering laboratory equipment company situated in Enschede, Netherlands. There, she is responsible for strategy and operations. Dr. Roelofs obtained her MSc. degree in Applied Physics from the University of Twente with a specialization in Biophysical Engineering. She completed her PhD in Lab-on-Chip technology at the University of Twente in 2015.

Locsense focuses on the development of in-vitro sensing equipment. Currently Locsense’ team consists of 10 persons. Since 2019, Locsense has successfully launched new products, including their flagship device, the Artemis Impedance spectrometer / TEER detector.

Headshot of Eline Geervliet

Eline Geervliet, PhD

Application Scientist, Locsense

At Locsense, Eline Geervliet, bridges the gap between scientific research and practical applications. There, her primary goal is to improve in vitro detection of several toxicological models, thereby reducing the necessity for in vivo testing. Eline Geervliet completed her PhD at the University of Twente, in close collaboration with RWTH Aachen, where she developed novel in vitro models to mimic different organs to investigated novel therapeutic targets. She received her Masters at the University of Twente, where she investigated pH-responsive smart polymersomes for MMP-1 delivery and treatment of liver cirrhosis.

Host:

David Yarmosh, headshot.

David Yarmosh, MS

Lead Bioinformatician, ATCC

David Yarmosh is a lead bioinformatician in ATCC’s Sequencing and Bioinformatics Center. He’s a graduate of New York University’s Tandon School of Engineering. He has been working in large data aggregation and analysis since 2013 and microbial genomics with a focus on biosurveillance R&D efforts since 2016. David has led international training exercises in Peru and Senegal, sharing metagenomic analytical capabilities. His interests include genomics database construction, metadata collection, drug resistance mechanisms, bioinformatics standards, and machine learning. Since joining ATCC in 2020, David has worked extensively in SARS-CoV-2 classification, epidemiology, and genomics evaluation, including enhanced and uniform variant reporting. He has contributed more broadly to genomics reporting and analytical standardization and he has helped develop the podcast Behind the Biology, which he now hosts.

Browse our featured resources

Scientist using pipette to fill well-plate Presentation

Innovative Microphysiological Model Using HepatoXcell™ Primary Human Hepatocytes and Locsense Artemis

Explore our Exhibitor-Hosted Session from SOT & ToxExpo 2025 to learn about a novel microphysiological model designed to mimic the gut-hepatic barrier.

More
Female scientist conducting an experiment lab. Poster

Exploring the performance of HepatoXcell™ in two liver-chip technologies

This is a poster presented at the 2025 MPS World Summit that demonstrates the application of HepatoXcell™ primary human hepatocytes in two liver-chip technologies.

More
Gloved hands of young modern scientist preparing all the necessary equipment before carrying out new clinical experiment Poster

Innovative Microphysiological Model Using HepatoXcell™ Primary Human Hepatocytes and Locsense Artemis

This is a poster presented at SOT & ToxExpo 2025 that demonstrates the use of HepatoXcell™ as a microphysiological model.

More
Scientist using pipette to fill well-plate

HepatoXcell™ by ATCC logo

Primary human hepatocytes are considered the gold standard for in vitro liver models due to their high predictive value in drug metabolism and toxicity studies. They can provide early insights into how a drug will behave in the human body, potentially reducing the risk of adverse effects in clinical trials. ATCC hepatocytes are meticulously isolated and characterized to ensure the highest quality and performance for your drug development and toxicity testing needs. Try our HepatoXcell™ primary human hepatocytes and media today!

Learn more